Stock Taper
NeuroSense Therapeutics Ltd., a clinical-stage biotech in Herzliya, Israel, develops treatments for neurodegenerative diseases, with lead product PrimeC in Phase IIa for ALS and pipeline candidates for Parkinson’s and Alzheimer’s.

PrimeC is a clinical-stage, oral combination of FDA-approved ciprofloxacin and celecoxib, targeting ALS mechanisms, completed Phase 2b trials, and is NeuroSense's leading candidate for neurodegenerative disease treatment.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
NERV | $4.84 | COMPARE |
RLYB | $16.81 | COMPARE |
NRXS | $6.00 | COMPARE |
TAOX | $3.89 | COMPARE |
ENLV | $1.35 | COMPARE |
XCUR | $1.29 | COMPARE |
CVKD | $1.54 | COMPARE |
CLGN | $0.36 | COMPARE |